Tweet
J Infect Dis
. 2023 Aug 31;228(Supplement_2):S126-S135.
doi: 10.1093/infdis/jiad286. Long COVID After Bamlanivimab Treatment
Teresa H Evering 1 , Carlee B Moser 2 , Nikolaus Jilg 3 , Eunice Yeh 2 , Busola Sanusi 2 , David A Wohl 4 , Eric S Daar 5 , Jonathan Z Li 3 , Paul Klekotka 6 , Arzhang Cyrus Javan 7 , Joseph J Eron 4 , Judith S Currier 8 , Michael D Hughes 2 9 , Davey M Smith 10 , Kara W Chew 8 ; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
Background: Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.
Methods: Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.
Results: Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.
Conclusions: Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.
Clinical trials registration: NCT04518410.
Keywords: bamlanivimab; clinical trial; long COVID; postacute sequelae of SARS-CoV-2 infection (PASC); symptom.
. 2023 Aug 31;228(Supplement_2):S126-S135.
doi: 10.1093/infdis/jiad286. Long COVID After Bamlanivimab Treatment
Teresa H Evering 1 , Carlee B Moser 2 , Nikolaus Jilg 3 , Eunice Yeh 2 , Busola Sanusi 2 , David A Wohl 4 , Eric S Daar 5 , Jonathan Z Li 3 , Paul Klekotka 6 , Arzhang Cyrus Javan 7 , Joseph J Eron 4 , Judith S Currier 8 , Michael D Hughes 2 9 , Davey M Smith 10 , Kara W Chew 8 ; ACTIV-2/A5401 Study Team
Collaborators, Affiliations
- PMID: 37650236
- DOI: 10.1093/infdis/jiad286
Background: Prospective evaluations of long COVID in outpatients with coronavirus disease 2019 (COVID-19) are lacking. We aimed to determine the frequency and predictors of long COVID after treatment with the monoclonal antibody bamlanivimab in ACTIV-2/A5401.
Methods: Data were analyzed from participants who received bamlanivimab 700 mg in ACTIV-2 from October 2020 to February 2021. Long COVID was defined as the presence of self-assessed COVID symptoms at week 24. Self-assessed return to pre-COVID health was also examined. Associations were assessed by regression models.
Results: Among 506 participants, median age was 51 years. Half were female, 5% Black/African American, and 36% Hispanic/Latino. At 24 weeks, 18% reported long COVID and 15% had not returned to pre-COVID health. Smoking (adjusted risk ratio [aRR], 2.41 [95% confidence interval {CI}, 1.34- 4.32]), female sex (aRR, 1.91 [95% CI, 1.28-2.85]), non-Hispanic ethnicity (aRR, 1.92 [95% CI, 1.19-3.13]), and presence of symptoms 22-28 days posttreatment (aRR, 2.70 [95% CI, 1.63-4.46]) were associated with long COVID, but nasal severe acute respiratory syndrome coronavirus 2 RNA was not.
Conclusions: Long COVID occurred despite early, effective monoclonal antibody therapy and was associated with smoking, female sex, and non-Hispanic ethnicity, but not viral burden. The strong association between symptoms 22-28 days after treatment and long COVID suggests that processes of long COVID start early and may need early intervention.
Clinical trials registration: NCT04518410.
Keywords: bamlanivimab; clinical trial; long COVID; postacute sequelae of SARS-CoV-2 infection (PASC); symptom.